NCT01875250View on ClinicalTrials.gov

Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 22, 2013

Primary Completion Date

September 1, 2019

Study Completion Date

February 28, 2020

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

PROSTVAC-F (Fowlpox)/TRICOM

A recombinant fowlpox virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.

BIOLOGICAL

PROSTVAC-V (Vaccinia)/TRICOM

A recombinant vaccinia virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.

DRUG

Enzalutamide (Xtandi)

An androgen receptor inhibitor.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01875250 - Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer | Biotech Hunter | Biotech Hunter